Targeted Diet and Exercise Program Puts Early-Onset Type 2 Diabetes into Remission for More Than Half of Young Adults in New Clinical Trial
A carefully structured combination of restrictive dieting and supervised physical activity has demonstrated a remarkable ability to put type 2 diabetes into remission among younger adults, according to landmark clinical trial findings. Presented at the Annual Meeting of the European Association for the Study de Diabetes (EASD) and published simultaneously in The Lancet Regional Health Americas, the research reveals that more than half of participants who completed an intensive lifestyle intervention achieved diabetes remission within just six months. This starkly contrasts with the mere 4% of participants who achieved similar outcomes under standard medical care.
The international study was spearheaded by Professor Kaberi Dasgupta, Director of the Division of General Internal Medicine at McGill University in Montreal, Canada, alongside Professor Thomas Yates of the University of Leicester in the UK, and an extensive team of clinical researchers. Their findings suggest that pairing a scientifically calculated low-calorie diet with regular, supervised aerobic and resistance exercise could fundamentally alter the traditional clinical trajectory of early-onset type 2 diabetes (EOT2D), which is clinically defined as a diagnosis occurring in individuals under the age of 45.
The Escalating Crisis of Early-Onset Type 2 Diabetes
For decades, type 2 diabetes was viewed primarily as a disease of aging. However, global epidemiological trends over the past twenty years have revealed a deeply concerning surge in diagnoses among teenagers, twenty-somethings, and younger adults. This manifestation of early-onset type 2 diabetes is clinically recognized as a far more aggressive and volatile form of the metabolic disease compared to its late-onset counterpart.
Patients diagnosed with EOT2D typically experience an accelerated decline in glycemic control, meaning their bodies lose the ability to regulate blood sugar much faster. Consequently, these individuals develop debilitating microvascular and macrovascular complications—such as neuropathy, retinopathy, nephropathy, and cardiovascular disease—decades earlier in life. This cumulative burden of disease ultimately translates to a significantly shortened life expectancy and a diminished quality of life during their prime working and family-building years.
Medical literature has previously established that very low-energy diets (LEDs) can induce sharp drops in blood sugar, enabling some patients to enter remission without relying on glucose-lowering pharmaceuticals. In clinical terms, diabetes remission is defined as a state where a patient’s blood sugar drops below the diagnostic threshold for diabetes (an HbA1c level under 6.5% or 48 mmol/mol) and remains there for at least three consecutive months without the aid of medication. While remission is a transformative clinical milestone, researchers emphasize that it is not a permanent cure; the underlying physiological vulnerability remains, and without ongoing weight and lifestyle management, the condition can easily return.
Chronology and Methodology of the RESET for Remission Trial
To determine whether the addition of a structured exercise regimen could amplify the metabolic benefits of low-calorie diets, researchers designed a rigorous, randomized open-label clinical trial known as the RESET for Remission study. Recruitment and enrollment for the trial officially commenced on September 24, 2021, and data collection concluded on June 6, 2025.
The trial was conducted across three specialized academic research centers located in England and Canada—specifically affiliated with the University of Leicester, McGill University in Montreal, and the University of Alberta in Edmonton. The study enrolled a total of 96 ethnically diverse adult participants aged 18 to 45 who had been diagnosed with early-onset type 2 diabetes and clinical obesity, but who were not currently dependent on insulin therapy. Of the total cohort, 50 individuals were randomly assigned to the intensive lifestyle intervention group, while 46 individuals were assigned to a control group receiving standard medical care.
The baseline demographics of the cohort reflected the modern demographic reality of the disease: the intervention group comprised 24 females and 26 males with a mean age of 38 years and a baseline body mass index (BMI) averaging 35.2 kg/m². The control group included 21 females and 25 males with comparable baseline metrics. Despite the logistical challenges of conducting intensive lifestyle trials, retention was exceptionally high, with 86 participants—or 90% of the original cohort—successfully completing the final 24-week assessments.
A Closer Look at the Intensive Lifestyle Intervention
The 24-week intervention was divided into two distinct, highly managed phases designed to transition participants from rapid weight loss to sustainable long-term weight maintenance.
During the first 12 weeks, participants in the intervention arm underwent a medically supervised protocol that involved discontinuing all glucose-lowering and blood pressure medications (provided they did not exhibit albuminuria, a marker of protein in the urine indicating potential kidney stress). Their daily energy intake was sharply restricted to between 800 and 900 calories, composed of 30% protein, 50% carbohydrate, and 20% fat. To ensure safety and compliance, participants were instructed to consume at least two liters of calorie-free fluids daily and were provided access to fiber-based laxatives to counteract common side effects like constipation.
For the first two weeks of this restrictive phase, all conventional meals were entirely replaced with clinically formulated nutritional products—specifically Optifast in the UK and ProtiDiet in Canada. From weeks three through 12, participants maintained the exact same strict calorie limit but regained a degree of dietary flexibility by incorporating one conventional meal per day, alongside specialized nutritional products. This meal required strict adherence to daily targets, including 60 to 90 grams of total protein, one portion of fruit, and two portions of non-starchy vegetables.
Simultaneously, the exercise protocol required participants to engage in supervised aerobic and resistance training sessions twice per week, complemented by one independent exercise session each week during the first 12 weeks.
In the second phase of the trial, spanning weeks 13 through 24, participants transitioned away from rapid weight reduction and focused instead on stabilizing and maintaining their newly achieved weight loss, while continuing their independent exercise routines.
Striking Clinical Outcomes and Statistical Findings
At the conclusion of the 24-week trial period, the data revealed a profound statistical divergence between the intervention group and the standard care control group.
To qualify for diabetes remission, participants were required to demonstrate an HbA1c level below 6.5% (48 mmol/mol) while maintaining total abstinence from all glucose-lowering medications for a minimum of 12 consecutive weeks. In an intentionally conservative statistical approach, researchers factored all missing data points as non-remitters.
The results showed that 27 out of the 50 participants in the diet-and-exercise program successfully achieved diabetes remission, translating to an impressive remission rate of 54%. In stark contrast, only two out of the 46 participants in the standard care control group reached the same clinical benchmark, representing just 4% of the cohort. After adjusting for relevant demographic and baseline statistical factors, researchers calculated that individuals enrolled in the intensive lifestyle program were 21 times more likely to achieve diabetes remission than those receiving standard medical management.
Furthermore, physical metrics confirmed dramatic improvements in body composition. Among the 47 intervention participants with available weight tracking data, average body weight plummeted from 100.7 kg to 92.3 kg—representing an average net reduction of 8.4 kg over the six-month period. Conversely, the 43 control participants with available weight data started at an average baseline weight of 103.2 kg and lost an average of just 1.2 kg, finishing at 102.0 kg.
Statistical adjustments demonstrated that the intervention group lost an average of 7.5 kg more weight than the control group. Crucially, a volumetric breakdown of this weight loss indicated that an additional 6.6 kg of the reduction came strictly from body fat, proving that the lifestyle program successfully targeted adipose tissue rather than merely stripping water weight.
Safety Profile and Managing Side Effects
While the clinical outcomes were overwhelmingly positive, the intensive nature of the program was not without physiological tolls. However, the trial documented no severe adverse events throughout the 24-week duration.
Minor to moderate adverse events were significantly more frequent among participants in the lifestyle intervention arm. At least one adverse event was recorded in 43 of the 50 intervention participants, compared to just six out of the 46 participants in the standard care control group. The vast majority of these complaints manifested during the initial weeks of the very-low-calorie diet and included transient symptoms such as constipation, headaches, dizziness, and fatigue. Clinical supervisors noted that these symptoms were generally mild, self-limiting, and resolved naturally as participants’ bodies adapted to the radical dietary shift.
The Critical Role of Muscle Preservation During Weight Loss
One of the most scientifically innovative aspects of the RESET for Remission trial was its deliberate focus on protecting lean muscle mass during a period of rapid caloric restriction.
Historically, individuals undergoing aggressive weight loss programs—particularly those utilizing very-low-calorie diets—experience significant reductions in both fat mass and fat-free mass, which includes skeletal muscle. Clinical data from previous weight loss studies frequently demonstrate that when individuals inevitably regain weight over time, the body tends to recover proportionally more fat tissue than lean tissue. Over successive cycles of weight loss and regain, this phenomenon can lead to a progressive deterioration of muscle mass and physical strength, elevating the long-term risk of sarcopenia and metabolic dysfunction.
To counter this physiological trap, the research team integrated targeted resistance training directly into the primary phase of the weight loss protocol. The trial’s findings indicate that combining dietary restriction with progressive resistance exercise successfully prevents the severe muscle wasting typically associated with rapid slimming.
"Our RESET for Remission study targeted muscle during the intensive weight loss phase through resistance training, and our findings indicate fat-free mass and muscle preservation is achievable with rapid weight loss," the study authors noted. "Preserving muscle during remission-oriented weight loss may have important implications for long-term metabolic health, physical function, and disease trajectory. This requires examination in a longer-term study."
Broader Implications and Expert Perspectives
The successful outcomes of the trial have elicited widespread commentary from the global endocrinology and public health communities. Experts point out that as the global prevalence of early-onset type 2 diabetes continues to rise, traditional treatment paradigms centered solely on lifelong pharmacological management must be re-evaluated.
By achieving high remission rates, reducing systemic body fat, preserving muscular integrity, enhancing cardiovascular fitness, and simultaneously improving patient-reported psychological well-being, the combined lifestyle approach offers a holistic alternative. Furthermore, researchers emphasize that stabilizing metabolic health and achieving remission can be particularly transformative for younger women who are planning a pregnancy or who possess the potential for future family planning, significantly lowering the risks associated with gestational hyperglycemia.
Despite these promising breakthroughs, study authors maintain a note of scientific caution. The current trial was restricted to a 24-week window within a closely monitored clinical trial environment. Consequently, future research initiatives must focus on longitudinal studies to evaluate whether patients can successfully maintain their weight loss, preserve their muscle mass, and sustain diabetes remission over multi-year periods after returning to the complexities of everyday, unmonitored life.
As the medical community digests these findings, the message from the research team remains clear: "As the prevalence of early-onset type 2 diabetes rises globally, our findings highlight an opportunity to re-evaluate treatment paradigms and support scalable implementation of integrated dietary and exercise interventions for remission. Our approach may be particularly valuable in those seeking or with potential for pregnancy. It warrants further evaluation in longer term studies in real-world settings."
